Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis.

Wang W, Zhou X, Kwong JSW, Li L, Li Y, Sun X.

Sci Rep. 2017 May 11;7(1):1717. doi: 10.1038/s41598-017-01965-0.

2.

Update on Safety Issues Related to Antihyperglycemic Therapy.

Carpio GR, Fonseca VA.

Diabetes Spectr. 2014 May;27(2):92-100. doi: 10.2337/diaspect.27.2.92.

3.

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.

Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, Vyas P, Ranvir R, Patel PR.

Pharmacol Res Perspect. 2015 Jun;3(3):e00136. doi: 10.1002/prp2.136. Epub 2015 May 4.

4.

Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease.

Chang E, Park CY, Park SW.

J Diabetes Investig. 2013 Nov 27;4(6):517-24. doi: 10.1111/jdi.12107. Epub 2013 Jul 1. Review.

5.

Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes.

Nwose OM, Jones MR.

Clin Med Insights Endocrinol Diabetes. 2013 Dec 8;6:75-9. doi: 10.4137/CMED.S12590. Review.

6.

Diabetes: glycaemic control in type 2 (drug treatments).

Gorter KJ, van de Laar FA, Janssen PG, Houweling ST, Rutten GE.

BMJ Clin Evid. 2012 Oct 11;2012. pii: 0609. Review.

7.

Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes.

Viswanathan V, Mohan V, Subramani P, Parthasarathy N, Subramaniyam G, Manoharan D, Sundaramoorthy C, Gnudi L, Karalliedde J, Viberti G.

Clin J Am Soc Nephrol. 2013 Feb;8(2):225-32. doi: 10.2215/CJN.06330612. Epub 2012 Nov 26.

8.

Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.

Hoffmann BR, El-Mansy MF, Sem DS, Greene AS.

J Med Chem. 2012 Oct 11;55(19):8260-71. doi: 10.1021/jm301204r. Epub 2012 Sep 28.

9.

Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S.

Neuropsychopharmacology. 2012 Aug;37(9):2093-100. doi: 10.1038/npp.2012.58. Epub 2012 May 2.

10.

Failure or success of electronic search strategies to identify adverse effects data.

Golder S, Loke YK.

J Med Libr Assoc. 2012 Apr;100(2):130-4. doi: 10.3163/1536-5050.100.2.012. No abstract available.

11.

AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.

Schäfer HL, Linz W, Falk E, Glien M, Glombik H, Korn M, Wendler W, Herling AW, Rütten H.

Acta Pharmacol Sin. 2012 Jan;33(1):82-90. doi: 10.1038/aps.2011.165.

12.

Therapeutic Implications of PPARgamma in Cardiovascular Diseases.

Hasegawa H, Takano H, Komuro I.

PPAR Res. 2010;2010. pii: 876049. doi: 10.1155/2010/876049. Epub 2010 Aug 12.

13.

Thiazolidinediones and cardiovascular risk - a question of balance.

Erdmann E, Charbonnel B, Wilcox R.

Curr Cardiol Rev. 2009 Aug;5(3):155-65. doi: 10.2174/157340309788970333.

14.

Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.

Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S; DREAM investigators.

Diabetes Care. 2010 Oct;33(10):2250-3. doi: 10.2337/dc10-0452. Epub 2010 Jul 13.

15.

Insulin-Mimetic Action of Rhoifolin and Cosmosiin Isolated from Citrus grandis (L.) Osbeck Leaves: Enhanced Adiponectin Secretion and Insulin Receptor Phosphorylation in 3T3-L1 Cells.

Rao YK, Lee MJ, Chen K, Lee YC, Wu WS, Tzeng YM.

Evid Based Complement Alternat Med. 2011;2011:624375. doi: 10.1093/ecam/nep204. Epub 2011 Mar 10.

16.

Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities.

Sivitz WI, Yorek MA.

Antioxid Redox Signal. 2010 Apr;12(4):537-77. doi: 10.1089/ars.2009.2531. Review.

Supplemental Content

Support Center